Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Payables (2016 - 2026)

Aytu Biopharma has reported Payables over the past 15 years, most recently at $14.3 million for Q4 2025.

  • Quarterly Payables fell 9.24% to $14.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.3 million through Dec 2025, down 9.24% year-over-year, with the annual reading at $10.6 million for FY2025, 16.59% down from the prior year.
  • Payables was $14.3 million for Q4 2025 at Aytu Biopharma, up from $12.3 million in the prior quarter.
  • Over five years, Payables peaked at $25.1 million in Q1 2023 and troughed at $9.4 million in Q3 2021.
  • The 5-year median for Payables is $14.7 million (2022), against an average of $14.6 million.
  • Year-over-year, Payables skyrocketed 125.3% in 2023 and then tumbled 51.92% in 2024.
  • A 5-year view of Payables shows it stood at $15.6 million in 2021, then grew by 15.41% to $18.0 million in 2022, then crashed by 36.15% to $11.5 million in 2023, then skyrocketed by 36.63% to $15.7 million in 2024, then fell by 9.24% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Payables are $14.3 million (Q4 2025), $12.3 million (Q3 2025), and $10.6 million (Q2 2025).